Angion
US-based Angion is a biopharmaceutical firm developing novel therapeutics for acute organ injuries and fibrosis.
Founded
1998US-based Angion is a biopharmaceutical firm developing novel therapeutics for acute organ injuries and fibrosis.
Founded in Uniondale, United States, Angion is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel small molecule therapeutics aimed at treating acute organ injuries and fibrotic diseases. The company's core mission is to address significant unmet medical needs through innovative treatments that improve patient outcomes and quality of life. Angion's primary focus is on developing therapies that can mitigate the effects of organ damage and fibrosis, thereby offering new hope to patients suffering from these debilitating conditions.
Notable affiliated individuals include experienced professionals from the biopharmaceutical industry who bring a wealth of expertise to the company. Angion has attracted investment from prominent venture capital firms and strategic partners, underscoring confidence in its potential. Key achievements include advancing its lead therapeutic candidates through critical stages of clinical development, demonstrating promising efficacy and safety profiles. Overall, Angion's impact lies in its commitment to transforming the treatment landscape for acute organ injuries and fibrotic diseases, potentially offering groundbreaking solutions that could significantly enhance patient care.
Companies similar to Angion include Angiex, Pliant Therapeutics, Blade Therapeutics and NGM Biopharmaceuticals.
Angion was founded in 1998.
Angion's headquarters is located in Uniondale, NY, US.
Angion's most recent funding round was for $25M (USD) in February 2021.
As of Feb 5, 2021, Angion has raised a total of $84.3M (USD).
Angion has 25 employees as of Feb 10, 2024.
Blade Therapeutics
